Extract

Funding sources: this study was supported in part by the National Institutes of Health through K24AR064310 (J.M.G.), T32AR007465‐32 (S.K.G. and J.W.), K23AR068433 (J.T.) and K23DK093556 (M.R.D.), as well as an unrestricted grant from Pfizer to the trustees of the University of Pennsylvania (J.M.G.).

Conflicts of interest: M.R.D. has received research funding from Genentech and Mallinckrodt (unrelated to this study) and has a consultancy agreement with Infiniti Medical. J.T. has received a research grant from Pfizer (unrelated to this study) and payment for continuing medical education work related to psoriasis. J.M.G. in the previous 12 months has served as a consultant for AbbVie, AstraZeneca, Celgene Corp, Coherus, Eli Lilly, Janssen Biologics (formerly Centocor), Sanofi, Merck, Novartis Corp., Endo and Pfizer Inc., receiving honoraria; receives research grants (to the trustees of the University of Pennsylvania) from AbbVie, Amgen, Eli Lilly, Janssen, Novartis Corp., Regeneron and Pfizer Inc.; and received payment for continuing medical education work related to psoriasis. J.M.G. is a joint patent holder of resiquimod for the treatment of cutaneous T‐cell lymphoma.

You do not currently have access to this article.